(NASDAQ: ALLR) Allarity Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 105.68%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,278.94%.
Allarity Therapeutics's earnings in 2026 is -$11,249,000.On average, 3 Wall Street analysts forecast ALLR's earnings for 2026 to be -$15,579,781, with the lowest ALLR earnings forecast at -$14,968,809, and the highest ALLR earnings forecast at -$16,038,010.
In 2027, ALLR is forecast to generate -$15,742,070 in earnings, with the lowest earnings forecast at -$15,124,734 and the highest earnings forecast at -$16,205,072.